We designed a randomized , controlled prospective study aimed at comparing efficacy and tolerability of ezetimibe + fenofibrate treatment versus pravastatin monotherapy in dyslipidemic HIV-positive ( HIV + ) patients treated with protease inhibitors ( PIs ) .